Brief: Enlivex Therapeutics Says Qtrly Net Loss Was $5.7 Mln, Compared To Net Loss Of $3.4 Mln For Q3 2021
05/12/2022 13:25
Dec 5 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND
PROVIDES A BUSINESS UPDATE
* ENLIVEX THERAPEUTICS LTD - EXISTING CASH AND CASH
EQUIVALENTS
SUFFICIENT TO FUND OPERATING EXPENSES AND CAPEX REQUIREMENTS
THROUGH Q3 OF 2024
* ENLIVEX THERAPEUTICS LTD - QTRLY NET LOSS WAS $5.7
MILLION, AS
COMPARED TO A NET LOSS OF $3.4 MILLION FOR Q3 2021
Source text for Eikon: ID:nGNX8H5W71
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment